Endogenex
PLYMOUTH, MN · Healthcare · 27 employees
Endogenex is a privately held, clinical-stage company headquartered in Minneapolis, MN. Endogenex was founded in partnership with Mayo Clinic to develop therapies to improve outcomes for people living with type 2 diabetes. Endogenex focuses on the principle that effective treatment for type 2 diabetes can extend beyond pharmaceutical options, correct metabolic function, and help people regain cont
Funding history
- Series series c — $50.0M — Mar 2026
- Funding Round — $69.6M — Jun 2024
- Funding Round — $18.3M — Oct 2023
- Funding Round — $9.2M — Feb 2023
- Funding Round — $12.0M — Apr 2021
Recent signals
- Mar 25, 2026: Raised $50.0M in Series series c
- Jan 14, 2025: Endogenex Appoints Krissy Wright as Chief Financial Officer (CFO) to Lead Financial Strategy and Corporate Development
- Jun 24, 2024: Raised $69.6M
- Oct 17, 2023: Raised $18.3M
- Feb 24, 2023: Raised $9.2M
- Apr 20, 2021: Raised $12.0M
- Dec 06, 2018: Raised $12.8M
- Feb 14, 2018: Raised $140K in Series pre-seed
See plans & pricing → Track Endogenex’s funding, hiring, and signals — with verified contacts — on Fundz.